Mepact mifamurtide regulatory update

The U.K.'s NICE issued a final appraisal determination (FAD) recommending against the use of Mepact mifamurtide from Takeda in combination with postoperative multi-agent chemotherapy to treat high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection - its approved indication. The decision is in line with a July preliminary appraisal (see BioCentury, July 12). ...